Professors Svetlana Mojsov and Carlos Kenig, among other eminent figures, were selected to win the 48th session of the prize.

The NFL playoffs are nearly here. Ahead of Week 17's Sunday slate of games, 12 of the 14 postseason spots have been clinched. Only a few other fanbases outside of those dozen franchises have a chance ...

'Tis the season for holiday cheer, gifts and time spent with loved ones and football. Fans of all franchises may have woken up to gifts showing off their favorite team. For fans of nearly half the ...

Nearly four decades ago, Francis Young, chief administrative law judge at the Drug Enforcement Administration (DEA), concluded that marijuana did not belong in Schedule I of the Controlled Substances ...

JACKSONVILLE, Fla. — The status of marijuana is on the verge of changing after an executive order signed by President Trump on Thursday. Right now, marijuana remains on the federal Schedule One list ...

President Donald Trump signs an executive order that seeks to lower the drug classification of marijuana, and Florida CFO Blais Ingoglia outlines a series of bills aimed at "increasing accountability" ...

President Donald Trump signed an executive order Thursday to fast-track the reclassification of cannabis, which would pave the way for the Food and Drug Administration to study its medicinal uses. "It ...

NEW YORK CITY (PIX11) — Everything can change in a New York minute. Mayor-elect Zohran Mamdani has revealed his “first order of business” for when he takes office on Jan. 1. Mamdani touched on his ...

First Lady Melania Trump successfully organized a new Executive Order entitled, “Fostering the Future for American Children and Families.” Under Mrs. Trump’s leadership, this unprecedented ...

EULAR - The European Alliance of Associations for Rheumatology - has developed the first classification criteria for hemochromatosis arthropathy (HA) from a unique derivation cohort using rigorous ...

Advances ongoing development of PALI-2108 across fibrostenotic Crohn’s disease and ulcerative colitis, with Phase 2 IND submission planned for H1 2026 Carlsbad, CA, Oct. 20, 2025 (GLOBE NEWSWIRE) -- ...

First dual-acting anti-inflammatory and anti-fibrotic candidate in development for FSCD, a condition with no approved therapies Topline safety, PK, and PD data anticipated in Q1 2026 Advances ongoing ...